NCT05974150 Real World Treatment Experience of Patients With Breast, Lung, Ovarian, Multiple Myeloma, or Acute Myelogenous Leukemia Using Remote Symptom Monitoring
| NCT ID | NCT05974150 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Carevive Systems, Inc. |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 25 participants |
| Start Date | 2023-07-19 |
| Primary Completion | 2026-11-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 25 participants in total. It began in 2023-07-19 with a primary completion date of 2026-11-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this study is to create a data set to add to Carevive's registry from real world clinical and patient reported data collected using an electronic care planning system (CPS) with remote symptom monitoring that is used in routine care for cancer patients on active treatment. Patients will complete a baseline survey in person using a secured device or remotely using their own electronic device in a location of their choice. Weekly electronic patient reported outcome (PRO) surveys are collected from the patients using the Carevive platform for a minimum of 12 weeks. Patients may continue weekly surveys as long as they are receiving treatment.
Eligibility Criteria
Inclusion Criteria: * All participants must be 18 years of age or older. * Subjects may be any stage and anywhere in the treatment continuum. * Subject participants must have a diagnosis of a breast, lung, AML, ovarian cancer or multiple myeloma. * Subjects must be able to complete on-line surveys using a cell phone, tablet, or computer. * All participants must be able to understand English. Exclusion Criteria: * Any patient who cannot understand written or spoken English. * Any patient without the ability to complete on-line surveys using a cell phone, tablet, or computer. * Any patient on a treatment clinical trial. * Any prisoner and/or other vulnerable persons as defined by NIH (45 CFR 46, Subpart B, C and D).
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05974150 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05974150 currently recruiting?
Yes, NCT05974150 is actively recruiting participants. Contact the research team at Julie.Scott@Carevive.com for enrollment information.
Where is the NCT05974150 trial being conducted?
This trial is being conducted at New Haven, United States, Evanston, United States, Chapel Hill, United States, Durham, United States and 3 additional locations.
Who is sponsoring the NCT05974150 clinical trial?
NCT05974150 is sponsored by Carevive Systems, Inc.. The trial plans to enroll 25 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.